Peptides for Muscle Growth: What Actually Works (Evidence Review)

Growth hormone has a reputation for building muscle. That reputation is partly earned — and partly inflated by decades of gym mythology.

The reality: GH does influence body composition, but it’s not the straight line from “more GH” to “more muscle” that most people assume. GH-releasing peptides work by telling your pituitary gland to produce more of its own growth hormone, and the downstream effects on muscle tissue depend on the specific peptide, the dose, and — honestly — your training and nutrition. If you’re exploring peptide therapy for performance goals, understanding what the research actually shows matters more than following forum hype.

This guide breaks down every peptide category with real clinical data. We’ll cover which ones have evidence behind them, which are overhyped, and what realistic results look like. For a broader look at all available compounds, see our list of peptides and what they do.

Key Takeaways

• GH-releasing peptides increase lean body mass by 1-3 kg over 3-12 months in clinical studies — meaningful, but not dramatic [1][2]
• CJC-1295 + ipamorelin is the most commonly prescribed stack for muscle-focused goals, targeting two separate GH pathways [3][4]
• Tesamorelin is the only FDA-approved GHRH analog — meta-analysis shows +1.42 kg lean mass with simultaneous fat reduction [2]
• None of these peptides replace training. They amplify what exercise already does by improving recovery, GH pulsatility, and protein synthesis signaling

Table of Contents

1. How GH Peptides Build Muscle
2. CJC-1295: The Long-Acting GHRH Analog
3. Ipamorelin: The Clean Secretagogue
4. The CJC-1295 + Ipamorelin Stack
5. Tesamorelin: The FDA-Approved Option
6. GHRP-2 and GHRP-6: The Older Generation
7. MK-677 (Ibutamoren): The Oral Option
8. BPC-157 and TB-500: Recovery Peptides
9. Comparing Peptides to Direct HGH
10. Realistic Expectations and Timelines
11. Side Effects and Safety
12. FAQ
13. Sources

How GH Peptides Build Muscle

Growth hormone doesn’t directly make muscles bigger. The pathway is more indirect than that.

When your pituitary releases GH, it travels to the liver and triggers production of IGF-1 (insulin-like growth factor 1). IGF-1 is the actual muscle-building signal — it stimulates muscle protein synthesis, promotes satellite cell activation, and reduces protein breakdown [5].

GH also shifts your metabolism toward using fat for fuel instead of amino acids, which has a “protein-sparing” effect. You retain more of what you eat as muscle tissue rather than burning it for energy [6].

Here’s where peptides fit in. Rather than injecting synthetic GH (which provides a flat, non-physiological dose), GH-releasing peptides stimulate your pituitary to release its own GH in natural pulses. This preserves the feedback loops your body uses to regulate hormone levels. Two categories of peptides do this through different mechanisms:

GHRH analogs (CJC-1295, tesamorelin, sermorelin) mimic the brain’s natural “release GH” signal. They press the gas pedal.

GH secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin) activate the ghrelin receptor, which amplifies the pituitary’s response to GHRH and suppresses somatostatin — the brake on GH release.

Using both together produces a synergistic GH pulse that’s larger than either alone [7]. This is why stacking is standard practice in peptide therapy.

CJC-1295: The Long-Acting GHRH Analog

CJC-1295 is a modified version of the first 29 amino acids of natural GHRH. The modification (called Drug Affinity Complex, or DAC) extends its half-life from minutes to roughly 6-8 days [1].

A Phase 2 trial in 21 healthy adults showed that a single dose of CJC-1295 increased mean GH levels 2-10 fold and IGF-1 levels 1.5-3 fold, with effects lasting up to 28 days [1]. That’s dramatically longer than natural GHRH, which is cleared in under 10 minutes.

The “no DAC” version (also called Modified GRF 1-29) has a shorter half-life of about 30 minutes. This is actually what most clinics prescribe, because it produces sharper GH pulses that more closely mimic natural physiology. The DAC version maintains elevated GH around the clock, which blunts pulsatility.

What it means for muscle: Sustained IGF-1 elevation drives protein synthesis over days, not hours. But CJC-1295 is rarely used alone — it’s almost always paired with a secretagogue like ipamorelin to maximize each GH pulse.

For different peptide types and how they’re categorized, we have a dedicated breakdown.

Ipamorelin: The Clean Secretagogue

Ipamorelin stands out from other GH secretagogues for one reason: selectivity.

In the original 1998 characterization study, researchers found that ipamorelin released GH with the same potency as GHRP-6 — but without raising cortisol, prolactin, or ACTH, even at doses 200 times higher than the effective GH-releasing dose [4]. No other secretagogue comes close to that level of selectivity.

This matters for muscle goals because cortisol is catabolic — it breaks down muscle tissue. Peptides that raise cortisol alongside GH are partially working against themselves. Ipamorelin sidesteps this entirely.

We go deeper on ipamorelin’s specific benefits in a dedicated guide, including dosing protocols and what to expect week by week.

The CJC-1295 + Ipamorelin Stack

This is the most widely prescribed peptide combination for muscle and body composition goals. The logic is pharmacologically sound: CJC-1295 (the GHRH signal) and ipamorelin (the ghrelin receptor signal) activate two separate pathways that converge on the pituitary [7].

The result is a GH pulse substantially larger than either peptide produces alone. Research on GHRH + GHS combinations consistently shows this synergistic effect across multiple secretagogue pairings [7].

Our full CJC-1295 + ipamorelin stack guide covers the clinical trial data, dosing protocols, and how this combination compares to direct HGH therapy.

Typical protocol:

• CJC-1295 (no DAC): 100-300 mcg per injection
• Ipamorelin: 100-300 mcg per injection
• Timing: 1-3 times daily, with the most important dose at bedtime (to amplify the natural nocturnal GH surge)
• Cycle: 8-12 weeks on, followed by a washout period

Most patients report noticing improved sleep quality within the first 1-2 weeks — which makes sense, since GH release is highest during deep sleep. Body composition changes typically become measurable by week 6-8.

Tesamorelin: The FDA-Approved Option

Tesamorelin (brand name Egrifta) is the only GHRH analog with FDA approval. It’s indicated for HIV-associated lipodystrophy, but the body composition data is relevant to anyone interested in GH peptides.

A 2026 meta-analysis pooling data from multiple randomized controlled trials found that tesamorelin treatment produced [2]:

• +1.42 kg lean body mass (95% CI: 1.13-1.71, P<0.001)
• Significant reduction in visceral adipose tissue
• Increased skeletal muscle area and density in responders

A separate study published in the Journal of Acquired Immune Deficiency Syndromes confirmed that tesamorelin not only reduced trunk fat but increased muscle cross-sectional area [8].

The 2 mg daily subcutaneous dose used in clinical trials is higher than what most peptide clinics prescribe. But the data confirms the basic principle: sustained GHRH stimulation can meaningfully shift body composition toward more muscle and less fat.

Tesamorelin’s effects overlap with peptides for weight loss and fat loss, since GH-mediated changes affect both sides of the equation simultaneously.

GHRP-2 and GHRP-6: The Older Generation

Before ipamorelin, GHRP-2 and GHRP-6 were the go-to secretagogues. They work through the same ghrelin receptor but are less selective [9].

GHRP-6 produces strong GH release but also spikes cortisol, prolactin, and — most noticeably — appetite. The hunger effect is intense and hits within 20 minutes of injection. For someone trying to bulk, this can be useful. For anyone watching calories, it’s a problem.

GHRP-2 is more potent for GH release than GHRP-6 and causes less appetite stimulation, but it still raises cortisol and prolactin to a degree that ipamorelin doesn’t [9].

Hexarelin is the most potent GHS studied in humans but causes rapid desensitization — GH response drops significantly after several weeks of continuous use [10]. It also has the most side effects of the group.

A 2020 review in Translational Andrology and Urology noted that these older GHRPs showed measurable effects on body composition in clinical settings, with GHRP-2 demonstrating improvements in lean mass and fat reduction [9]. But the side effect profiles have pushed most prescribers toward ipamorelin.

MK-677 (Ibutamoren): The Oral Option

MK-677 isn’t technically a peptide — it’s a non-peptide ghrelin receptor agonist that you take by mouth. But it belongs in this discussion because it’s the most studied GH secretagogue for body composition.

In a 12-month randomized controlled trial, MK-677 (25 mg daily) increased fat-free mass by an average of 1.6 kg compared to placebo [11]. Another study in older adults showed a 3 kg increase in lean mass over 12 months, driven primarily by IGF-1 elevation [12].

The catch: MK-677 increases appetite (it activates the ghrelin receptor, after all) and can worsen insulin sensitivity with prolonged use. It also raises cortisol, unlike ipamorelin [11].

MK-677 is not FDA-approved and is classified as a research compound. It’s also on WADA’s prohibited list.

BPC-157 and TB-500: Recovery Peptides

These don’t directly raise GH, so they don’t “build muscle” in the traditional sense. But they’re worth mentioning because muscle growth depends on recovery as much as stimulus.

BPC-157 and TB-500 are used for tendon, ligament, and soft tissue healing. Faster recovery means you can train harder and more frequently — which, over months, translates to more muscle. Our wolverine peptide stack guide covers the BPC-157 + TB-500 combination in detail.

For athletes dealing with joint issues that limit training, these recovery-focused peptides can indirectly support muscle-building goals by keeping you in the gym.

Comparing Peptides to Direct HGH

This is the question most people are really asking: why not just take HGH?

Direct HGH (somatropin) provides a flat dose of exogenous growth hormone. It works, but it comes with tradeoffs:

Factor	GH Peptides	Direct HGH
GH pattern	Pulsatile (natural)	Flat (non-physiological)
Pituitary function	Preserved	Suppressed over time
IGF-1 increase	Moderate (1.5-3x)	Higher (dose-dependent)
Side effects	Milder	Water retention, joint pain, insulin resistance
Cost	$200-500/month	$600-2,000/month
Legal status	Research compound	Prescription (Schedule III)

GH peptides produce smaller IGF-1 increases than direct HGH at equivalent clinical doses. But they maintain your pituitary’s ability to produce GH on its own, which matters for long-term use [6].

Realistic Expectations and Timelines

Here’s what the clinical data actually supports for GH peptide therapy combined with resistance training:

Weeks 1-2: Improved sleep quality and recovery between workouts. This is the earliest and most consistent effect reported.

Weeks 4-8: Subtle body composition changes become noticeable — slightly fuller muscles, reduced water retention giving a “tighter” appearance. Fat loss may be more visible than muscle gain initially.

Weeks 8-16: Measurable lean mass increases in the range of 1-3 kg, depending on the peptide combination, training intensity, and nutrition. Fat mass typically decreases simultaneously [2][11].

What you won’t get: Peptides won’t produce steroid-like results. A realistic 12-week outcome with proper training and nutrition is 2-4 lbs of additional lean mass above what training alone would produce. That’s meaningful but requires honest expectations.

Proper peptide handling matters too — learn how to reconstitute peptides correctly to maintain potency.

Side Effects and Safety

GH-releasing peptides are generally well-tolerated, but they’re not without risks.

Common side effects (10-20% of users):

• Injection site redness or irritation
• Water retention (usually resolves in 2-3 weeks)
• Transient headaches
• Numbness or tingling in extremities (carpal tunnel-like)

Less common but notable:

• Increased hunger (especially with GHRP-6 and MK-677)
• Mild insulin resistance with prolonged use
• Joint stiffness at higher doses
• Fatigue or lethargy (paradoxically, despite improved sleep)

Contraindications:

• Active cancer or history of cancer (GH and IGF-1 can promote tumor growth)
• Diabetic retinopathy
• Uncontrolled diabetes
• Pregnancy or breastfeeding

None of the GH-releasing peptides discussed here (except tesamorelin) are FDA-approved for any indication. They’re prescribed off-label or used under research protocols. Long-term safety data beyond 12-18 months is limited for most compounds.

For a thorough look at side effects across all peptide categories, see our peptide side effects guide.

FAQ

Do peptides actually build muscle or just increase water weight?▼

Both, initially. GH increases intracellular water retention, which accounts for some early “gains.” But clinical studies measuring lean body mass via DEXA scan — which distinguishes water from actual tissue — consistently show real muscle tissue increases of 1-3 kg over 3-12 months [2][11]. The water retention effect usually stabilizes within 2-3 weeks.

What’s the best peptide stack for muscle growth?▼

CJC-1295 (no DAC) + ipamorelin is the most commonly prescribed combination, and for good reason — it targets both GHRH and ghrelin receptor pathways with minimal side effects [3][4]. Adding a recovery peptide like BPC-157 can support training volume. There’s no single “best” — it depends on your specific goals, tolerance, and medical history.

How long do peptides take to show results for muscle?▼

Sleep and recovery improvements: 1-2 weeks. Visible body composition changes: 6-8 weeks. Measurable lean mass increases: 8-16 weeks. These timelines assume consistent resistance training and adequate protein intake (1.6-2.2 g/kg/day). Without training, peptides produce minimal muscle effects.

Are peptides for muscle growth legal?▼

GH-releasing peptides exist in a regulatory gray area. They’re not controlled substances in most jurisdictions, but they’re also not FDA-approved for muscle building. They can be prescribed off-label by licensed physicians. They’re prohibited by WADA and most professional sports organizations. Tesamorelin is the only FDA-approved GHRH analog, but only for HIV-associated lipodystrophy.

Can peptides replace steroids for muscle building?▼

No. Anabolic steroids directly activate androgen receptors in muscle tissue, producing much larger and faster hypertrophy responses than anything GH peptides can achieve. Peptides work through the GH/IGF-1 axis, which has a more modest effect on muscle size. Peptides are better thought of as recovery and body composition tools, not muscle-building drugs in the steroid sense.

Sources

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed

2. Meta-analysis: Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy. PubMed. 2026. PubMed

3. Ionescu M, Bhatt DL. Growth hormone-releasing hormone and growth hormone secretagogues. Growth Horm IGF Res. 2010;20(2):97-105.

4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed

5. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-568.

6. Hermansen K, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Rec Pat Endocr Metab Immune Drug Discov. 2017. PMC

7. Bowers CY. Synergistic release of growth hormone by GHRP and GHRH. J Pediatr Endocrinol. 1993;6(3-4):325-331.

8. Stanley TL, et al. The growth hormone releasing hormone analogue tesamorelin decreases muscle fat and increases muscle area in adults with HIV. J Acquir Immune Defic Syndr. 2024.

9. Lee J, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMC

10. Arvat E, et al. Preliminary evidence for the existence of a functional interaction between the GH-releasing peptides and the GH-releasing hormone receptor in humans. J Endocrinol Invest. 1994;17(3):209-213.

11. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611.

12. Murphy MG, et al. Effect of alendronate and MK-677 on body composition in older adults. J Clin Endocrinol Metab. 2001;86(3):1116-1125.

13. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. NEJM